HIGHLIGHTS
- who: Wu Dawei and colleagues from the Research Institute for Medicines Medicine, Italy have published the research work: Unblinding at disease progression in double-blinded randomized controlled cancer drug clinical trials: A controversy requires more attention, in the Journal: (JOURNAL)
- future: To fully establish the decision-making mechanism in the future additional studies are needed such as surveys on the awareness of different stakeholders to this issue implementation of the unblinding procedures at patient level in real world and cohort studies exploring the effect of blinding to the prognosis of trial participants.
SUMMARY . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.